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Abstract
Introduction:  A  key  step  of  cancer  development  is  the  progressive  accumulation  of  genomic
changes resulting  in  disruption  of  several  biological  mechanisms.  Carcinoma  ex-pleomorphic
adenoma  (CXPA)  is  an  aggressive  neoplasm  that  arises  from  a  pleomorphic  adenoma.  CXPA
derived from  a  recurrent  PA  (RPA)  has  been  rarely  reported,  and  the  genomic  changes  associated
with these  tumors  have  not  yet  been  studied.
Objective:  We  analyzed  CXPA  from  RPAs  and  RPAs  without  malignant  transformation  using  array-
comparative  genomic  hybridization  (array-CGH)  to  identify  somatic  copy  number  alterations  and
affected genes.
Methods:  DNA  samples  extracted  from  FFPE  tumors  were  submitted  to  array-CGH  investigation,
and data  was  analyzed  by  Nexus  Copy  Number  Discovery  Edition  v.7.
Results:  No  somatic  copy  number  alterations  were  found  in  RPAs  without  malignant  trans-
formation.  As  for  CXPA  from  RPA,  although  genomic  profiles  were  unique  for  each  case,  we
detected some  chromosomal  regions  that  appear  to  be  preferentially  affected  by  copy  number Please cite this article as: Mariano FV, Giovanetti K, Saccomani LF, Del Negro A, Kowalskic LP, Krepischi AC, et al. Carcinoma ex-
pleomorphic adenoma derived from recurrent pleomorphic adenoma shows important difference by array CGH compared to recurrent
pleomorphic adenoma without malignant transformation. Braz J Otorhinolaryngol. 2016;82:687--94.
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alterations.  The  first  case  of  CXPA-RPA  (frankly  invasive  myoepithelial  carcinoma)  showed  copy
number alterations  affecting  1p36.33p13,  5p  and  chromosomes  3  and  8.  The  second  case  of
CXPA-RPA (frankly  invasive  epithelial-myoepithelial  carcinoma)  showed  several  alterations  at
chromosomes  3,  8,  and  16,  with  two  amplifications  at  8p12p11.21  and  12q14.3q21.2.  The  third
case of  CXPA-RPA  (minimally  invasive  epithelial-myoepithelial  carcinoma)  exhibited  amplifica-
tions at  12q13.3q14.1,  12q14.3,  and  12q15.
Conclusion:  The  occurrence  of  gains  at  chromosomes  3  and  8  and  genomic  amplifications  at  8p
and 12q,  mainly  those  encompassing  the  HMGA2,  MDM2,  WIF1,  WHSC1L1,  LIRG3,  CDK4  in  CXAP
from RPA  can  be  a  significant  promotional  factor  in  malignant  transformation.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published  by
Elsevier Editora  Ltda.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Carcinoma  ex-adenoma  pleomórfico  derivado  de  adenoma  pleomórfico  recorrente
mostra  diferenc¸a  importante  por  array  CGH  em  comparac¸ão  com  adenoma
pleomórfico  recorrente  sem  transformac¸ão maligna
Resumo
Introduc¸ão: Uma  etapa  fundamental  do  desenvolvimento  do  câncer  é  o  acúmulo  progressivo
de alterac¸ões  genômicas,  resultando  na  ruptura  de  vários  mecanismos  biológicos.  Carcinoma
ex-adenoma  pleomórfico  (CXAP)  é  uma  neoplasia  agressiva  que  surge  a  partir  de  um  adenoma
pleomórfico.  O  CXAP  derivado  de  um  AP  recorrente  (APR)  foi  raramente  relatado  e,  até  o
momento, as  alterac¸ões  genômicas  associadas  a  esses  tumores  não  foram  estudados.
Objetivo:  Avaliar  as  diferenc¸as  entre  os  CXAPs  decorrentes  de  APRs  e  os  APRs  sem
transformac¸ões malignas  usando  hibridizac¸ão  genômica  comparativa  em  microarrays  (array
Comparative  Genomic  Hibridization  ----  aCGH)  a  fim  de  identificar  alterac¸ões  no  número  de
cópias somáticas  e  os  genes  afetados.
Método:  Amostras  de  DNA  extraídas  de  tumores  provenientes  de  tecido  emblocado  em  parafina
foram submetidos  à  investigac¸ão  com  a  técnica  aCGH,  e  os  dados  foram  analisados  com  o  Nexus
Copy Number  Discovery  Edition  v.7.
Resultados:  Não  observamos  alterac¸ões  no  numero  de  cópias  somáticas  nos  APRs  sem
transformac¸ão maligna.  Quanto  ao  CXAP  de  APR,  embora  os  perfis  genômicos  sejam  exclusivos
para cada  caso,  detectamos  algumas  regiões  cromossômicas  que  pareciam  ser  preferencial-
mente afetadas  por  alterac¸ões  no  número  de  cópias.  O  primeiro  caso  de  CXAP-APR  (carcinoma
mioepitelial  francamente  invasivo)  apresentou  alterac¸ões  no  numero  de  cópias  afetando
1p36.33p13,  5p  e  cromossomos  3  e  8.  O  segundo  caso  de  CXAP-APR  (carcinoma  epitelial-
mioepitelial  francamente  invasivo)  apresentou  várias  alterac¸ões  nos  cromossomos  3,  8  e  16,
com duas  amplificac¸ões  em  8p12p11.21  e  12q14.3q21.2.  O  terceiro  caso  de  CXAP-APR  (carci-
noma epitelial-mioepitelial  minimamente  invasivo)  apresentou  amplificac¸ões  em  12q13.3q14.1,
12q14.3,  e  12q15.
Conclusão:  A  ocorrência  de  ganhos  de  cromossomos  3  e  8,  e  as  amplificac¸ões  genômicas  em  8p
e 12q,  principalmente  aquelas  que  englobam  os  HMGA2,  MDM2,  WIF1,  WHSC1L1,  RG3,  CDK4  no
CXAP decorrente  de  APR  podem  ser  fatores  promocionais  significativos  para  a  transformac¸ão
maligna.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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leomorphic  adenoma  (PA)  is  the  most  common  tumor  of
he  salivary  glands,  accounting  for  about  60--70%  of  such
eoplasms.  It  is  a  benign  tumor  with  high  risk  of  recurrence
nd  malignant  transformation.1 The  recurrence  risk  ranges
rom  0.4%  to  45%,  depending  on  the  surgical  technique2:
0--45%  after  enucleation,  2--5%  following  parotid  lobec-
omy,  and  up  to  0.4%  after  radical  parotidectomy.3 Recurrent
m
o
tleomorphic  adenoma  (RPA)  presumably  derives  either
rom  capsule  rupture,  incomplete  resection  of  micro-
copic  extensions  beyond  the  pseudocapsule,  or  multifocal
rigin.4
Permanent  facial  nerve  injury  risk,  multinodular  feature,
nd  increased  frequency  of  new  recurrence  are  factors  that
ake  the  treatment  of  RPA  difficult.5 Furthermore,  the  risk
f  malignant  transformation  increases  with  the  duration  of
he  disease.6,7 To  date,  CXPA  arising  from  RPA  has  been  rarely
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TCarcinoma  ex-pleomorphic  adenoma  derived  from  recurrent
reported  and  these  studies  have  focused  on  the  histopatho-
logical  and  clinical  features  of  the  lesions.8
The  recurrence  of  tumor  can  be  caused  by  either  increase
in  the  number  or  complexity  of  genetic  abnormalities
or  acquisition  of  promoting  mutations  to  the  malignant
change.  Cancer  is  driven  by  somatically  acquired  muta-
tions,  and  chromosomal  rearrangements  are  thought  to
accumulate  gradually  over  time.9 Whole-genome  screening
such  as  array-CGH  can  be  applied  to  disclose  copy  number
alterations  which  could  identify  molecular  basis  for  carcino-
genesis.
Herein,  the  aim  of  this  study  was  to  investigate  by  array
comparative  genomic  hybridization  (aCGH)  the  genomic  pro-
file  of  copy  number  alterations  associated  with  three  cases
of  carcinoma  ex-pleomorphic  adenoma  (CXPA)  originated
from  RPA,  discover  their  involved  genes,  and  compare  these
findings  to  four  cases  of  RPA  without  malignant  transforma-
tion.
Methods
The  current  study  was  carried  out  in  accordance  with  the
ethical  guidelines  of  our  institution  (Process  n◦ CEP/FOP
002/2011).  DNA  samples  were  extracted  from  a  1.5  mm
diameter  punch  of  paraffin  embedded  tumor  tissues  using
Qiagen  extraction  kit  (Qiagen  GmbH,  Hilden,  Germany),
according  to  the  manufacturer’s  recommendations.  The
protocol  included  deparaffinization  with  xylene,  followed
by  methanol  washings,  and  24-hour  incubation  in  1moL/L
sodium  thiocyanate.  Subsequently,  the  tissue  pellet  was
dried  and  digested  for  1.5  day  in  a  lysis  buffer  with  high
proteinase  K  level  (60  L).  Samples  were  column-purified
before  buffer  elution.
Tumor  and  reference  DNA  (pooled  from  blood  of  differ-
ent  healthy  donors;  Promega,  Madison,  WI,  USA)  samples
were  differently  labeled  using  the  Enzo  Genomic  DNA  Label-
ing  kit  according  to  the  manufacturer’s  instructions.  Five
hundred  g  of  labeled  tumor  and  reference  DNA  were  co-
hybridized  to  a  180  K  oligonucleotide  array  (SurePrint  G3
Human  CGH  Microarray  Kit  4  ×  180  K  design  22060,  Agilent
Technologies,  Palo  Alto,  CA,  USA),  following  manufacturer
procedures.  This  design  contains  24,011  exonic  probes.
Microarray  images  were  obtained  by  Agilent  Microarray
Scanner  Bundle,  and  data  was  extracted  using  the  Feature
Extraction  software  v.9.1  (Agilent  Technologies,  Santa  Clara,
CA,  USA).
Array-CGH  data  was  analyzed  using  the  software  Nexus
Copy  Number  Discovery  edition  v.7.0.  Genomic  copy  number
alterations  were  called  based  on  the  FASST2  segmenta-
tion  algorithm  (significance  threshold  set  on  5  ×  10−8) with
threshold  log2 ratios  of  0.2  or  0.8  for  gains  or  high-copy
gains,  respectively,  and  −0.2  or  −1.0  for  losses  or  homozy-
gous  losses,  respectively.
ResultsClinic-pathological  data  of  the  CXPA  from  RPA
The  first  patient  (case  1)  was  a  72  year-old  man  referred  to
our  hospital  for  evaluation  of  a  nodule  in  the  parotid  gland
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easuring  9.0  cm  ×  8.0  cm  with  a  reported  time  of  evolu-
ion  of  two  years.  The  patient  had  undergone  resection  of
 PA  five  years  ago.  During  clinical  examination,  palpable
ymph  nodes  and  subjacent  skin  invasion  were  observed.
here  was  absence  of  oral  lesions.  Fine  needle  aspiration
iopsy  revealed  a  PA.  Tumor  was  excised  with  positive  sur-
ical  margins.  Histological  examination  showed  presence
f  PA  and  CXPA  regions.  The  neoplasm  was  classified  as  a
rankly  invasive  myoepithelial  carcinoma  (Fig.  1A  and  B).
he  patient  was  submitted  to  radiotherapy  and  no  recur-
ence  was  observed  in  58  months  of  follow-up.
The  second  patient  (case  2)  was  a  66  year-old  woman
eferred  to  our  hospital  complaining  of  a  tumor  in  the
arotid  region  for  an  unknown  time.  The  patient  had
ndergone  resection  of  a  PA  11  years  ago.  Clinical  exam-
nation  rules  out  the  presence  of  palpable  lymph  nodes
nd  oral  lesions.  Fine  needle  aspiration  biopsy  confirmed
he  presence  of  a  PA.  Tumor  excision  was  performed  but
he  margins  were  positive  surgically.  Histological  exam-
nation  showed  presence  of  PA  and  CXPA,  which  were
lassified  as  frankly  invasive  epithelial-myoepithelial  car-
inoma  (Fig.  1C  and  D).  There  is  no  follow-up  of  this
atient.
The  third  patient  (case  3)  was  a  30  year-old  woman
eferred  to  our  hospital  complaining  of  a  tumor  in  the
arotid  gland  with  two  years  of  duration.  The  patient  had
ndergone  resection  of  a  PA  16  years  ago.  During  clini-
al  examination,  palpable  lymph  nodes  and  oral  lesions
ere  not  observed.  Fine  needle  aspiration  biopsy  showed
resence  of  PA.  The  tumor  was  excised  with  negative  sur-
ical  margins.  The  histopathological  analysis  showed  PA
nd  CXAP  regions.  The  latter  was  a  minimally  invasive
pithelial-myoepithelial  carcinoma  (Fig.  1E  and  F).  There
s  no  follow-up  of  this  patient.
rray-CGH  analysis
he  cases  of  RPAs  did  not  show  somatic  copy  number  alter-
tions.  All  somatic  chromosomal  alterations  detected  in
XPAs  from  cases  1,  2  and  3  are  detailed  in  Table  1, as  well
s  affected  known  cancer  genes  according  to  the  Cancer
ene  Census  Sanger  (https://www.sanger.ac.uk/research/
rojects/cancergenome/census.html).  Fig.  2  presents  the
lobal  genomic  profile  of  copy  number  alterations  identified
n  CXPA  cases  1,  2  and  3.  The  first  CXPA  from  RPA  exhibited
p36.33p13  loss,  chromosomes  3  and  8  gains,  and  two  adja-
ent  chromosomal  rearrangements  affecting  5p15.33p13.1
loss)  and  5p13.1q13.1  (gain),  respectively.
The  second  case  of  CXPA  from  RPA  showed  a  more  com-
lex  genomic  pattern  with  several  copy  number  alterations
gains  and  losses)  affecting  chromosomes  3,  8  and  16.  Addi-
ionally,  this  sample  harbor  losses  at  5q14.3q33.1,  5q35.3,
0p15.3p13,  14q11.2q32.2,  20q13.12,  and  gains  at  6p22.2,
2q11.1q13.  Regions  of  high  copy  number  gains  (amplifica-
ions)  were  found  at  8p12p11.21  and  12q14.3q21.2  (Fig.  3A).
he  amplified  genes  included  among  others  WHSCILI  and
GFR1  at  8p,  and  HMGA2  and  MDM2  at  12q.
The  third  case  exhibited  losses  at  12q14.1q14.2  and
2q14.3q15,  and  amplifications  at  12q13.3q14.1,  12q.14.3
nd  12q15,  encompassing  CDK4,  LRIG3,  WIF1,  HMGA2  and
DM2  (Fig.  3B).
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Figure  1  Frankly  invasive  myoepithelial  carcinoma:  (A)  Island  of  myoepithelial  cells  infiltrating  the  tissue  (H&E  ×  10);  (B)  cords
of pleomorphic  myoepithelial  cells  surrounded  by  myxoid  stroma.  Note  the  reaction  against  thread  suture  from  previous  surgery  in
the top  right  side  of  the  image  (H&E  20×).  Frankly  invasive  epithelial-myoepithelial  carcinoma:  (C)  Proliferation  of  epithelial  and
myoepithelial  cells  in  a  nodular  growth  (H&E  10×);  (D)  Small  lumen  bounded  by  eosinophilic,  cuboidal,  intercalated  duct-like  cells.
These cells  are  surrounded  by  small  and  non-staining  cytoplasm  cells.  Note  the  maintenance  of  basal  cells  in  the  periphery  of  nest
cells surrounded  by  fibrous  septa  (H&E  20×).  Minimally  invasive  epithelial-myoepithelial  carcinoma:  (E)  Epithelial-myoepithelial
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f tumor  cells  and  ductal  structures  comprised  of  epithelial  and
iscussion
he  carcinogenesis  occurs  in  several  steps  through  genomic
hanges  that  result  in  loss  of  tumor  suppressor  functions,
he  activation  of  oncogenes  and/or  the  generation  of  fusion
enes  with  oncogenic  potential.10 These  alterations  gener-
te  clonal  expansion  resulting  in  phenotype  of  malignant
ancer  cells.11 Although  such  changes  can  occur  by  muta-
ions  or  genomic  rearrangements,  abnormal  chromosome
umbers  and  structures  have  also  been  well  reported  in  neo-
lastic  cells,  indicating  that  chromosome  instability  is  an
p
t
n)  eosinophilic,  hyalinized  basal  lamina  material  surrounds  nests
epithelial  cells  (H&E  20×).
mportant  aspect  of  cancer  cell  biology.10 Therefore,  copy
umber  alterations  can  be  an  auxiliary  tool  in  the  under-
tanding  about  carcinogenesis.
Malignant  transformation  of  recurrent  pleomorphic  ade-
oma  is  reported  in  1.5--23%  of  cases,  and  the  risk  appears
o  increase  with  time  and  number  of  recurrences.12 The
ccurrence  of  malignant  change  from  recurrence  of  the
leomorphic  adenoma  must  involve  the  acquisition  of  muta-
ions  over  a  period  of  time.
The  current  cases  exhibited  different  patterns  of  copy
umber  alterations,  and  it  is  important  to  emphasize  that
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Table  1  Somatic  copy  number  alterations  detected  by  array-CGH  in  three  cases  of  CXPA  from  RPA.
Chromosome  coordinates  (Hg19)  Event  type  Size
(Mb)
Cytoband  Genes
(n)
Known  cancer  genes  (CGCS)
Case  1
chr1:0-12,034,621-109,356,617  Loss  109  1p36.33-p13.3  1204  TNFRSF14,  PRDM16,  RPL22,  CAMTA1,
SDHB,  PAX7,  MDS2,  ARID1A,  LCK,
SFPQ,  THRAP3,  MYCL1,  MPL,
MUTYH,  TAL1,  CDKN2C,  EPS15,  JUN,
JAK1,  FUBP1,  BCL10
chr3:0-91,000,000  Gain  91.0 3p26.3-q11.1  646  SRGAP3,  FANCD2,  VHL,  PPARG,
RAF1,  XPC,  MLH1,  MYD88,  CTNNB1,
SETD2,  BAP1,  PBRM1,  FHIT,  MITF,
FOXP1
chr3:95,011,793-163,987,310  Gain  69.0 3q11.2-q26.1  490  TFG,  CBLB,  GATA2,  RPN1,  FOXL2,
WWTR1,  GMPS,  MLF1
chr3:164,108,626-198,022,430  Gain  34.0  3q26.1-q29  261  EVI1,  PIK3CA,  SOX2,  ETV5,  EIF4A2,
BCL6,  LPP,  TFRC
chr5:0-40,851,406  Loss  40.8  5p15.33-p13.1  187  IL7R,  LIFR
chr5:40,935,588-46,150,843  Gain  27  5p13.1-q13.1  125  IL6ST,  PIK3R1
chr8:0-43,647,122  Gain  146  8p23.3-q24.3  926  PCM1,  WRN,  WHSC1L1,  FGFR1,
HOOK3,  TCEA1,  PLAG1,  CHCHD7,
NCOA2,  HEY1,  COX6C,  EXT1,  MYC,
NDRG1,  RECQL4
Case 2
chr3:24,527,963-90,336,853  Loss  6.5  3p24.2-p11.1  451  MLH1,  MYD88,  CTNNB1,  SETD2,
BAP1,  PBRM1,  FHIT,  MITF,  FOXP1
chr3:93,529,103-101,960,258  Gain  0.8  3q11.1-q12.3  54  TFG
chr3:101,960,258-102,594,287  Loss  0.06  3q12.3  1
chr3:102,610,999-197,939,679  Gain  9.5  3q12.3-q29  628  CBLB,  GATA2,  RPN1,  FOXL2,  WWTR1,
GMPS,  MLF1,  EVI1,  PIK3CA,  SOX2,
ETV5,  EIF4A2,  BCL6,  LPP,  TFRC
chr5:85,168,149-152,581,242  Loss  6.7  5q14.3-q33.1  438  APC,  PDGFRB,  CD74
chr5:180,417,510-180,915,260  Loss  0.05  5q35.3  17
chr6:26,120,677-26,291,646  Gain  0.01  6p22.2  21
chr8:0-33,163,303  Loss  3.3  8p23.3-p12  255  PCM1,  WRN
chr8:35,142,906-39,877,924  Amplification  0.5  8p12-p11.21  36  WHSC1L1,  FGFR1
chr8:39,877,924-43,527,965  Gain  0.3  8p11.21-p11.1  28  HOOK3
chr8:47,553,667-146,364,022  Gain  9.8  8q11.1-q24.3  506  TCEA1,  PLAG1,  CHCHD7,  NCOA2,
HEY1,  COX6C,  EXT1,  MYC,  NDRG1,
RECQL4
chr10:0-13,151,933  Loss  1.3  10p15.3-p13  75  GATA3
chr12:66,133,957-76,156,328  Amplification  1.0  12q14.3-q21.2  55  HMGA2,  MDM2
chr14:20,595,449-98,566,915  Loss  7.8  14q11.2-q32.2  579  CCNB1IP1,  TRA@,  NKX2-1,  NIN,
KTN1,  GPHN,  TSHR,  TRIP11,
GOLGA5,  DICER1,  TCL6,  TCL1A
chr16:0-35,147,508  Gain  3.5  16p13.3-p11.1  532  TSC2,  CREBBP,  CIITA,  SOCS1,
TNFRSF17,  ERCC4,  MYH11,  PALB2,
IL21R,  FUS
chr16:46,367,235-90,237,661  Loss  4.3  16q11.2-q24.3  418  CYLD,  HERPUD1,  CDH11,  CBFB,
CDH1,  MAF,  CBFA2T3,  FANCA
chr20:45,505,668-46,151,351  Loss  0.6  20q13.12  5
chr22:17,296,232-51,274,523  Gain  3.3  22q11.1-q13.33  540  CLTCL1,  BCR,  SMARCB1,  MN1,
CHEK2,  EWSR1,  NF2,  MYH9,  PDGFB,
MKL1,  EP300
Case 3
chr12:57,993,000-60,129,343  Amplification  0.2  12q13.3-q14.1  25  CDK4,  LRIG3
chr12:60,129,343-64,578,600  Loss  4.4  12q14.1-q14.2  12
chr12:65,484,807-66,489,652  Amplification  0.1  12q14.3  8  WIF1,  HMGA2
chr12:66,489,652-68,720,923  Loss  2.2  12q14.3-q15  17
chr12:68,720,923-71,009,093  Amplification  0.2  12q15  26  MDM2
Amplification, high copy number gains are presented as genomic amplifications.
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Figure  2  Copy  number  alterations  detected  by  array-CGH  in  the  CXPAs  from  RPA  cases.  Array-CGH  genomic  profile  exhibiting  the
identified copy  number  alterations  of  case  1  (A),  case  2  (B)  and  case  3  (C).  The  x-axis  represents  probes  ordered  according  to  their
genomic position  from  chromosomes  1p  to  Xq  (each  chromosome  is  labeled  with  a  different  color).  The  y-axis  denotes  the  log2
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lest/reference  values  (genomic  gains  and  losses  are  plotted  abo
oftware Nexus  Copy  Number  7.0,  Biodiscovery).  The  arrows  in
istopathological  and  invasiveness  classifications  were  also
istinct.  However,  data  analysis  could  pinpoint  some  recur-
ent  copy  number  alterations  such  as  3q  and  8q  gains
cases  1 and  2),  and  importantly,  an  amplification  with
 minimum  common  region  at  12q14.3  (cases  2  and  3).
ases  1  and  2  were  frankly  invasive  carcinomas,  and
q  and  8q  gains  can  be  implicated  in  the  invasiveness
egree.  Cases  2  and  3  were  epithelial-myoepithelial  car-
inomas,  and  the  12q14.3  amplification  is  maybe  involved
ith  histopathological  subtype,  or  even  recurrence.  Case  2
xhibited  a  more  complex  pattern  of  rearrangements  con-
istent  with  the  histopathological  subtype  and  degree  of
nvasiveness.
Losses  of  1p21.3-p21.1,  5q23.2-q31.2,  8p,  10q21.3  and
5q11.2  were  found  by  Persson  et  al.13 in  a  study  of  a  group
u
a
r
r
A 
igure  3  (A)  Array-CGH  profile  of  chromosome  12  showing  the  hig
ase 1.  (B)  Array-CGH  profile  of  chromosome  12  showing  a  complex  p
umber (amplifications)  at  12q13.3q14.1  (0.2  Mb),  12q14.3  (0.1  Mb)
ow amplitude.r  below  the  0  baseline,  respectively;  images  adapted  from  the
e  the  high  copy  gains  (amplifications).
f  10  CXPAs;  however,  no  histopathological  classification  was
erformed.  We  find  losses  at  1p36.33-p13,  5p15.33-p13.1,
q14.3-q33.1,  5q35.3,  8p  and  10p15.3-p13.  Gain  of  8q12.1
PLAG1),  here  detected  in  two  cases,  has  been  reported  by
everal  authors.13--15
Amplifications  of  HMGA2,  MDM2,  and  deletions  of
q23.2q31.2  and  8q22.1q24.1  were  described  as  important
n  the  transition  from  PA  to  CXPA.13 We  observed  high  copy
ain  of  HMGA2,  MDM2,  CDK4,  WHSCIL1,  LRIG3  and  WIF1.
ll  the  amplified  genes  are  cancer  related,  according  to
he  Cancer  Gene  Census  Sanger  (https://www.sanger.ac.
k/research/projects/cancergenome/census.html).  HMGA2
nd  MDM2  amplification  were  found  in  two  of  our  cases,
einforcing  their  role  as  driver  genes  associated  with  recur-
ence  in  CXPA.
B
h  copy  number  gain  (amplification)  of  1Mb  at  12q14.3q21.2  in
attern  consisting  of  three  genomic  regions  exhibiting  high  copy
 and  12q15  (0.2  Mb),  interpolated  with  copy  number  losses  of
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1Carcinoma  ex-pleomorphic  adenoma  derived  from  recurrent
HMGA2  (human  high  mobility  group  A)  gene  encodes
a  non-histone  chromatin  protein  that  belongs  to  a  family
of  the  HMG  proteins,  which  are  overexpressed  in  malig-
nant  neoplasms  as  lung,  pancreatic,  oral  squamous  cell
carcinoma  and  breast  cancer.16--19 HMGA2  proteins  have
oncogenic  activity  through  several  mechanisms,  such  as
induction  of  E2F1  and  AP1  activity,  induction  of  cyclin  A
expression,  inactivation  of  p53  induced  apoptosis,  impair-
ment  of  DNA  repair,  enhancement  of  the  expression  of
proteins  involved  in  inflammation,  and  modulation  of  the
expression  of  microRNAs  and  genes  involved  in  epithelial-
mesenchymal  transition.20 Additionally,  HMGA  proteins  have
a  crucial  role  in  cell  transformation  because  when  their  syn-
thesis  is  blocked,  suppression  of  the  malignant  phenotype
occurs.  This  hypothesis  is  in  line  with  our  finding,  because
we  showed  the  amplification  of  HMAG2  from  a  minimally
invasive  case.
The  MDM2  (mouse  double  minute  2  homolog),  also  known
as  E3  ubiquitin  protein  ligase  Mdm2,  is  an  oncogene  which
encodes  a  Mdm2  protein,  which  is  a  key  negative  regu-
lator  of  the  p53  tumor  suppressor,  degrading  p53  protein
or  inhibiting  p53  activity.21 Inhibition  of  tumor  suppressor
genes  or  insensitivity  to  antigrowth  signals  occurs  in  most  of
the  tumors.  Incipient  cancer  cells  must  evade  these  antipro-
liferative  signals  if  they  are  to  prosper.11 The  current  work
showed  MDM2  already  amplified  in  our  minimally  invasive
case.  The  over  expression  of  MDM2  has  been  also  observed
in  a  wide  variety  of  human  tumors,  as  sarcoma,  leukemia,
breast  carcinoma,  melanoma,  and  glioblastoma.22
WHSC1L1  (Wolf-Hirschhorn  syndrome  candidate  gene-1)
encodes  a  short  protein  containing  one  PWWP  domain  and  is
expressed  in  many  tissues.  The  function  of  this  encoded  pro-
tein  is  unclear,  but  the  presence  of  PWWP  domain,  a  putative
site  for  protein-protein  interaction,  suggests  a  regulatory
role.23 WHSC1L1  has  already  been  identified  as  an  oncogene
and  it  is  amplified  and  overexpressed  in  lung  carcinoma.24
FGFRs  (fibroblast  growth  factor  receptors),  encoded
by  four  genes  (FGFR1,  FGFR2,  FGFR3,  and  FGFR4),  are
associated  with  many  biological  processes  such  as  organ
development,  cell  proliferation  and  migration.  Several  stud-
ies  have  described  a  role  of  FGFRs  in  tumorigenesis  due
to  the  regulation  of  diverse  tumorigenesis-related  pro-
cesses,  including  cell  survival,  proliferation,  inflammation,
metastasis  and  angiogenesis.  FGFR1  amplification  has  been
identified  mainly  in  lung  cancer.25
CDK4  (cyclin-dependent  kinases  4)  is  directly  involved
in  driving  the  cell  cycle.25 Amplification  of  CDK4  has  been
observed  in  several  malignancies  including  glioma,  breast
cancer,  lymphoma,  melanoma,  and  sarcoma.  Sometimes
CDK4  is  co-amplified  with  MDM2.  The  protein  encoded  by
this  gene  is  a  catalytic  subunit  of  the  protein  kinase  complex
that  is  important  for  cell  cycle  G1  phase  progression.26
LRIG  (human  leucine-rich  repeats  and  immunoglobulin-
like  domains)  gene  family  includes:  LRIG1,  LRIG2  and  LRIG3.
LRIG  expression  has  proven  to  be  of  prognostic  value  in
different  types  of  human  cancers,  including  breast  cancer,
early  stage  invasive  squamous  cervical  cancer,  cutaneous
squamous  cell  carcinoma,  oligodendroglioma,  and  astrocy-
toma.  LRIF1  functions  as  a  tumor  suppressor  gene,  while
little  is  known  about  the  functions  of  LRIG2  and  LRIG3.27
WIF1  is  Wnt  inhibitory  factor  1  gene.  The  protein  encoded
by  this  gene  functions  to  inhibit  WNT  proteins,  which  are
1morphic  adenoma  693
xtracellular  signaling  molecules  that  play  a  role  in  embry-
nic  development.  This  gene  acts  as  tumor  suppressor  gene,
nd  has  been  found  to  be  epigenetically  silenced  in  various
ancers.28
onclusion
n  conclusion,  we  identified  unique  genomic  profiles  of  copy
umber  alterations  among  three  cases  of  CXPA  from  RPA,
nd  differences  can  be  explained  due  to  histopathological
ubtypes  and  invasiveness  degrees.  However,  recurrent  gains
t  3q  and  8q,  and  amplifications  at  12q14.3  and  12q15  here
etected  can  be  the  promotional  factors  in  the  recurrence
f  the  disease.
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